<a href="https://www.fiercebiotech.com/biotech/eli-lilly-inks-deals-buy-3-vaccine-developers-38b" hreflang="en">Lilly inks deals to buy 3 vaccine developers for up to $3.8B as M&A spree continues</a>
Eli Lilly has announced the acquisition of three vaccine developers—Curevo, LimmaTech Biologics, and Vaccine Company—for up to $3.8 billion, aiming to enhance its infectious disease pipeline and focus on preventative measures against viral and bacterial pathogens. These acquisitions reflect Lilly's strategic shift towards building its vaccine portfolio, particularly in light of recent pressures on vaccine manufacturers.
Eli Lilly's recent $3.8 billion acquisition of Curevo, LimmaTech Biologics, and Vaccine Company underscores the strategic shift towards preemptive healthcare by expanding its infectious disease pipeline, particularly focusing on developing vaccines for both viral and bacterial pathogens. This move highlights an opportunity for stakeholders in healthtech and biotech sectors to explore investments and partnerships in vaccine development, especially given the increasing focus on preventing diseases like shingles, Staphylococcus aureus, and Epstein-Barr virus.